Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Reports First Quarter 2024 Results · Net Revenue up 70% to $23 Million vs. Q1 2023 · Global End User Demand Up 23% vs. Q1 2023 · Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced fi ...